Without much to go on, investors wonder how well the biotech's colon-cancer drug Xilonix works. So what: On the surface, the headline sounds so promising: "Xilonix Demonstrated Significant Clinical ...

With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain AUSTIN, Texas, Jan. 21, ...

AUSTIN, Texas, July 14, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today findings published in the prestigious American Heart Association’s journal, Circulation. The publication ...

XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen AUSTIN, ...

Interim Results of IL-1α True Human™ Monoclonal Antibody Demonstrate More Rapid Achievement of Glycemic Control Compared to Most Recent FDA Approved Therapy (Logo ...

XBiotech said its data in certain colon cancer patients were “positive,” but this has been ridiculed by some analysts and put its future European approval--which the data were to be used toward--under ...

Donors with Potent Natural Immunity Against the Virus are Identified as the Starting Point for XBiotech’s Drug Development Program to Treat COVID-19 AUSTIN, Texas, May 01, 2020 (GLOBE NEWSWIRE) -- ...

AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Xbiotech Inc. (XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000 in ...

After early findings were “not sufficient to meet efficacy,” XBiotech discontinued its phase III study of its novel candidate antibody therapy for colorectal cancer. 1. An Independent Data Monitoring ...

“The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are ...